Radiation Oncology Market Size, Share & Trends Analysis Report By Type (External Beam Radiation Therapy, Internal Beam Radiation Therapy), By Technology, By Application, By Region, And Segment Forecasts,

Published Date: May - 2025 | Publisher: MIR | No of Pages: 260 | Industry: advance materials | Format: Report available in PDF / Excel Format

View Details Buy Now 2999 Download Sample Ask for Discount Request Customization

Radiation Oncology Market Size & Trends

The size of the global radiation oncology market was measured at USD 10.56 billion in 2024 and is estimated to grow at a CAGR of 11.17% during 2025-2035. Major drivers of the market are technological innovation in radiotherapy equipment, increased incidence of cancer globally, and growing use of radiation therapy in the treatment of oncology. Recently, in March 2025, Actinium Pharmaceuticals launched ATNM-400, a novel radiotherapy for prostate cancer targeting non-prostate-specific membrane antigen (PSMA) pathways. The treatment employs the alpha-emitting radioisotope actinium-225 (Ac-225) to provide targeted radiation therapy.

In addition, the radiation oncology market is experiencing growing demand for radiotherapy as a result of the increasing global burden of cancer. As per the WHO, in the entire world, there were approximately 19.3 million people with cancer, and in 2022, 10 million died of cancer. Further, WHO in Europe approximated that there were 4.6 million new individuals diagnosed with different signs of cancers like prostate, breast, lung, colorectal, and brain, and approximately 2.1 million individuals in European countries died of the disease in 2020. Based on the American Cancer Society's report in 2022, breast cancer is the most prevalent occurring condition with an approximate 351,400 new cases in the U.S. of invasive and non-invasive breast tumors, respectively.

In the fast-paced market environment of the radiation therapy industry, major players are positioning themselves strategically to increase their market share. Accuray Incorporated received Chinese approval in October 2023 for its Tomo C radiation therapy system, creating new growth opportunities for the company in the market. This regulatory achievement demonstrates Accuray's dedication to growing its market share. In like manner, in June 2023, PharmaLogic Holdings Corp. signed a Master Services Agreement for the development and manufacturing of theranostic prospects VMT-01 and VMT-NET. These radiopharmaceuticals, in research and development stage, are intended for the diagnostic and treatment demands of metastatic melanoma and neuroendocrine cancers. This strategic partnership reflects PharmaLogic's commitment to helping bring cutting-edge solutions in the arena of oncology.

Report Coverage & Deliverables

PDF report & online dashboard will help you understand

  • Competitive benchmarking
  • Historical data & forecasts
  • Company revenue shares
  • Regional opportunities
  • Latest trends & dynamics

Market Concentration & Characteristics

Market development phase is at high level and with accelerating growth of pace. High innovation in level is what the radiation cancer treatment in oncology is exemplifying. Allowing this has been sophisticated techniques and methods used to reshape the treatment practice. Notable among these are major M&A endeavors being done by dominant market participants. Leading competitors are tactically collaborating to strengthen and enlarge their services, obtain access to new technologies, concentrate the fast-growing market, and respond to the growing strategic relevance of radiotherapy.

Within the radiation oncology market, prominent player IBA has made a major move in July 2023 by entering into collaboration with Apollo Proton Cancer Centre in India. The partnership plans to upgrade the competency of oncologists using proton beam therapy by implementing specialized training programs. This strategic partnership from IBA is a reflection of the increasing significance of skill development and knowledge-sharing in the radiation oncology market. The project is likely to positively influence the market dynamics by boosting the overall development of proton therapy applications. Therefore, other players in the industry would look into the same kind of collaborations or training schemes to remain competitive and part of the broader development and evolution of radiation oncology practices.

The market also faces growing regulatory oversight. The regulation of radiation exposure is by government agencies including the FDA, the Department of Transportation (DOT), the Environmental Protection Agency (EPA), and the Nuclear Regulatory Commission (NRC). Medical radiation administration devices are overseen by the Center for Devices and Radiologic Health (CDRH), while the application of radiation for medical purposes is controlled by the FDA. Radiation oncology devices are under the control of the Radiation Control for Health and Safety Act, 1968.

Code of Federal Regulations Title 21 administers the administration of radiopharmaceuticals in the U.S. Part 315 covers the diagnostic purposes and Part 361 the therapeutic purposes of radiopharmaceuticals separately in this title. The Nuclear Regulatory Commission (NRC) administers the usage of radiopharmaceuticals in 37 states as well. The NRC sanctions the use and ownership of radioactive source material, by product material, and special nuclear material.

CDRH regulates the use of radiopharmaceuticals. It also regulates the use of electron-emitting products, including medical devices. Radioisotopes that cause chemical effects, though, like Ra-223, are regulated by the Center for Drug Evaluation & Research, and those that are regarded as biologics, like I-131 and Y-90, are utilized for the treatment of non-Hodgkin's lymphoma and are regulated by the Center for Biologics Evaluation and Research.

Radiation therapy possesses major alternatives such as surgery and chemotherapy, which enhance most of the anticancer action but with increased side effects. Nevertheless, any technology being advanced in radiation therapy with enhanced technology with high efficiency might pose a risk to established interventions, e.g., IGRT, proton therapy, and 3D-conformity therapy, which urge patients to move towards advanced interventions. The absence of proper treatment alternatives for intricate cancers and higher side effects of therapies are likely to adversely affect the overall market growth.

In addition, the market is seeing more geographical expansion plans, for example, companies like Curium in June 2021, acquired Austrin to increase its foothold in Europe for its comprehensive range of life-saving diagnostic solutions. The deal will assist the company in augmenting its positron emission-tomography (PET) radiopharmaceutical business.

Type Insights

The market for external beam radiation therapy (EBRT), including compact advanced radiotherapy systems, and linear accelerators (Linac), accounted for the highest revenue share in the overall market in 2024 because of high adoption for the treatment of different forms of cancers. Additionally, EBRT products exhibit a high tumor-killing capacity in early stages compared to traditional therapies with less side effect. In addition, the speedy development of technologies and research into such technologies on different cancer therapies are creating increased demand for LINACs and MR-LINACs, thus driving the market growth.

Linear accelerator (Linac) employs microwave technology such as radar to kill tumor cells by sending high-energy electrons or X-rays close to the tumor site while sparing the surrounding healthy tissue. Novel linear accelerators' introduction drive market growth. For example, in May 2024, Elekta launched its new linear accelerator (linac) system Evo. Evo is equipped with cutting-edge high-definition, AI-enabled imaging and will support offline as well as online adaptive radiation therapy, as well as improved standard image-guided radiation treatments. The multi-patient, multi-spot, adaptive CT-Linac allows clinicians to customize radiation therapy methods for the individual requirements of each patient. Elekta launched Evo at ESTRO 2024, Europe's largest radiation oncology industry show, in Glasgow, Scotland, during the Annual Congress of the European Society for Radiotherapy and Oncology. 

Technology Insights

The IMRT segment accounted for the highest revenue share of 24.06% in 2024 due to the high demand for treatment and greater availability of technologically superior intensity-modulated radiotherapy (IMRT) in unmet treatment countries. Nevertheless, brachytherapy is predicted to be the quickest-growing segment during the forecast period by virtue of its high adoption rate and low risk of side effects.

3D-CRT directs the beams of radiation in a manner that the beams are of similar dimensions to that of the tumor and assist doctors in understanding the precise dimensions of the tumor, thus restricting harm to normal tissues. It provides delivery of a higher dose rate at the location of the tumor, thus making it more effective in shrinking and killing the tumor using a multi-leaf collimator (MLC) through a step-and-shoot mode. 3D-CRT is applied to treat head & neck, liver cancer, prostate, lung, and brain cancer.

The developments in brachytherapy offer accurate and localized dose delivery and customized treatment to patients. The technology is primarily applied for the treatment of prostate cancer. Its enhanced effectiveness and shorter setup time compared to traditional treatment methods are expected to propel the global brachytherapy segment. Also, favorable reimbursement policies of products used in brachytherapy decreased the cost of treatment, hence motivating patients to take up treatment. In February 2025, Saskatchewan Cancer Agency (SCA) launched its Interstitial High-Dose-Rate (HDR) Gynecological Brachytherapy program, a highly focused and specialized type of radiation therapy regarded as the gold standard for treating cancer of the cervix. With this program now accessible in Saskatchewan, patients no longer have to leave the province to be able to access this cutting-edge treatment.

Application Insights

The EBRT segment for prostate cancer had the highest revenue share of 58.65% in 2024 and is expected to continue its dominance during the forecast period. This is due to the growing global prevalence of cancer and rising usage of EBRT systems by hospitals and cancer centers. For example, in September 2021, Unicancer purchased several Radixact Systems of Accuray, Inc. with ClearRT with a goal to offer personalized treatment to patients in Europe. Unicancer is a network of French hospitals that treats 530,000 cancer patients each year.

The IBRT market is expected to see substantial growth during the forecast period because of the rising incidence of cancer in developing nations and growing product penetration. IBRT is predominantly applied in combination with breast cancer surgery. Brachytherapy for breast cancer utilizes various methods of device placement, including interstitial brachytherapy and intracavitary brachytherapy. Intracavitary brachytherapy is the most commonly performed method of breast cancer. Based on a study printed by the National Cancer Institute (NCI) revealed that whole breast irradiation (WBI) and accelerated partial-breast irradiation (APBI) reduce the incidence of cancer recurrences among breast cancer patients.IMRT is now the standard therapy for locally advanced head and neck cancer because of its conformality. In addition, gynecologic cancer is primarily managed with the assistance of different brachytherapy methods.

Regional Insights

North America radiation oncology industry dominated globally in terms of revenue share of 47.16% in 2024, owing to the favorable government initiatives and availability of technologically advanced radiotherapy equipment. Furthermore, active participation of key players to increase their market share in region is fueling the market growth. For instance, in December 2021, MVision AI entered partnership with Medron Medical Systems to distribute AI radiotherapy technology of MVision in Canada. The use of AI technology provides high accuracy, leading to improved patient outcomes.

Market Analysis

U.S. Radiation Oncology Market Trends

The radiation oncology industry in the U.S. benefits from strong technological innovation, high healthcare spending, and well-established cancer treatment infrastructure. Widespread adoption of advanced modalities like proton therapy and image-guided radiotherapy (IGRT) fuels demand. In addition, a rising geriatric population, increasing cancer incidence, and supportive reimbursement policies by Medicare and private insurers significantly contribute to market expansion. Active R&D and frequent clinical trials further enhance treatment precision and accessibility, making the U.S. a global leader in radiation oncology.

Europe Radiation Oncology Market Trends

The radiation oncology industry in Europe is driven by universal healthcare access, rising cancer prevalence, and government funding in public hospitals. Countries are investing in upgrading linear accelerators and integrating AI into radiotherapy workflows. EU-wide collaborations in oncology research promote innovation and early technology adoption. Public awareness campaigns and national screening programs further increase early diagnosis rates, boosting demand for radiation therapy. Integration of radiology networks across borders also improves access and standardization of cancer care.

The UK radiation oncology industry is growing due to NHS investments in cancer treatment infrastructure, including modernizing radiotherapy equipment. Government-backed initiatives like the Cancer Strategy emphasize early detection and rapid access to treatment. High incidence of breast and lung cancer, paired with centralized radiology networks, supports demand for radiotherapy. Integration of AI and adaptive radiotherapy, along with strong clinical trial participation, also bolsters innovation and adoption of cutting-edge technologies across NHS trusts.

Germany’s radiation oncology industry growth is driven by its robust healthcare system, widespread access to cancer care, and heavy investment in medical technology. High per capita healthcare expenditure and a strong manufacturing base support local development and deployment of advanced radiation systems. In addition, Germany’s aging population, coupled with increasing cancer diagnoses, drives treatment demand. Public-private partnerships in oncology research and continuous upgrades in treatment planning and delivery systems fuel market expansion in this technologically advanced nation.

Asia Pacific Radiation Oncology Market Trends

Asia Pacific radiation oncology industry is projected to be the fastest-growing globally over the forecast period due to improvements in healthcare infrastructure, increase in patient awareness levels, and high unmet patient needs. In addition, rising cancer burden and funding support to major players in the region are expected to offer lucrative opportunity for segment growth. According to Globocan report 2020, about 9.5 million new cancer cases were diagnosed, and 5.8 million died due to this disease in the region, increasing demand for radiotherapy to manage the impact of cancer in the countries.

China radiation oncology industry is expanding rapidly due to a rising cancer burden, large population base, and government efforts to improve oncology infrastructure. The Healthy China 2030 initiative supports investment in radiotherapy centers and training of oncologists. Urbanization and healthcare reforms have improved access to treatment. Domestic companies are also emerging with cost-effective radiotherapy solutions. Increased adoption of intensity-modulated radiation therapy (IMRT) and stereotactic body radiotherapy (SBRT) reflects technological progress and rising clinical standards.

Japan radiation oncology industry growth stems from a high elderly population, advanced medical infrastructure, and early adoption of precision radiotherapy technologies. Proton therapy is well-established and heavy government investment in cancer research accelerates development. Favorable reimbursement for advanced treatments and public awareness of early cancer detection drive clinical demand. In addition, collaboration between academia and industry supports innovation, while national health insurance ensures widespread access to sophisticated radiation oncology services.

Latin America Radiation Oncology Market Trends

Latin America radiation oncology industry growth is driven by rising cancer incidence, improving healthcare infrastructure, and growing public-private investment in cancer treatment. Countries like Brazil and Mexico are expanding radiotherapy centers and increasing access to IMRT and 3D conformal radiotherapy. International collaborations and training programs are improving clinical capabilities. Though limited by healthcare disparities, increased awareness and access to insurance are expanding patient access to radiation therapy across the region.

MEA Radiation Oncology Market Trends

The Middle East and Africa (MEA) radiation oncology industry is witnessing growth due to government investments in healthcare modernization and an increasing focus on oncology. Gulf countries like the UAE and Saudi Arabia are establishing state-of-the-art cancer centers, while Africa is seeing support from international NGOs and partnerships. Rising cancer awareness, urbanization, and expansion of private healthcare are improving access to radiation services. However, growth is uneven, with more rapid development in wealthier nations.

Key Radiation Oncology Company Insights

The leading players in radiation oncology industry are focusing on growth strategies, such as innovations with radiotherapy, product launches, and mergers & acquisitions. For instance, in June 2022, a company pioneering the use of biology-guided radiotherapy (BgRT), RefleXion Medical announced its first symposium focused on the power of using cancer biology to direct treatment planning and delivery for personalized radiotherapy. Moreover, in October 2021, Siemens Healthineers AG in collaboration with UC Health Proton Therapy Center completed enrollment for FAST-01 of Flash Therapy for the treatment of symptomatic bone metastases.

Market Size

Key Radiation Oncology Companies

The following are the leading companies in the radiation oncology market. These companies collectively hold the largest market share and dictate industry trends.

Recent Development

  • In April of 2025, ZEISS Medical Technology renewed its vow to drive state-of-the-art oncology by virtue of FDA's 510(k) approval of its INTRABEAM 700 system. Its new-generation platform provides robotic-enhanced precision in intraoperative radiation therapy (IORT). Digital-first design highlights, the INTRABEAM 700 simplifies workflow and increases connectivity-with substantial clinical value in the fields of neuro-oncology and breast cancer treatment.

    In March 2024, AstraZeneca made a definitive deal to buy Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical firm dedicated to creating next-generation radioconjugates (RCs). The deal is a major step forward for AstraZeneca's goal of transforming cancer treatment by moving away from conventional treatments like chemotherapy and radiotherapy to more targeted, precise forms of treatment.

    In February 2023, RefleXion Medical, a therapeutic oncology firm, reported that the U.S. Food and Drug Administration (FDA) approved the first marketing clearance for its SCINTIX biology-guided radiotherapy-a revolutionary therapy for both early- and late-stage cancers. To emphasize the importance of this breakthrough, the company will present a live-streamed event with its co-founder and CEO, who will explain the effect of SCINTIX therapy on cancer treatment.

Radiation Oncology Market Report Scope

Report Attribute

Details

Market size value in 2025

USD 12.48 billion

Revenue forecast in 2030

USD 21.19 billion

Growth Rate

CAGR of 11.17% from 2025 to 2035

Base year for estimation

2024

Historical data

2018 - 2023

Forecast period

2025 - 2035

Quantitative units

Revenue in USD million/billion and CAGR from 2025 to 2035

Report coverage

Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends

Segments covered

Type, technology, application, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; UK; Germany; France; Spain; Italy; Denmark; Sweden, Norway; Japan; China; India; Australia; South Korea;Thailand Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait

Key companies profiled

Varian Medical Systems, Inc.; Elekta AB; Accuray Incorporated; IBA Radiopharma Solutions; BD; Isoray Medical; Mevion Medical Systems, Inc.; Nordion Inc.; NTP Radioisotopes SOC Ltd.; Curium Pharma; Viewray Technologies, Inc.

Customization scope

 Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

 Avail customized purchase options to meet your exact research needs. Explore purchase options

Global Radiation Oncology Market Report Segmentation

Type Outlook (Revenue, USD Million, 2018 - 2035)

    • External Beam Radiation Therapy

      • Linear Accelerators (Linac)

      • Compact advanced radiotherapy systems

        • Cyberknife

        • Gamma Knife

        • Tomotherapy

      • Proton Therapy

        • Cyclotron

        • Synchrotron

    • Internal Beam Radiation Therapy

      • Brachytherapy

        • Seeds

        • Applicators and Afterloaders

        • Electronic Brachytherapy

      • Systemic Beam Radiation Therapy

      • Others

  • Technology Outlook (Revenue, USD Million, 2018 - 2035)

    • External Beam Radiation Therapy

      • Image-Guided Radiotherapy (IGRT)

      • Intensity Modulated Radiotherapy (IMRT)

      • Stereotactic Technology

      • Proton Beam Therapy

      • 3D Conformal Radiotherapy (3D CRT)

      • Volumetric Modulated Arc Therapy (VMAT)

    • Brachytherapy

      • Low-Dose Rate Brachytherapy

      • High-Dose Rate Brachytherapy

  • Application Outlook (Revenue, USD Million, 2018 - 2035)

    • External Beam Radiation Therapy

      • Prostate Cancer

      • Breast Cancer

      • Lung Cancer

      • Head and Neck Cancer

      • Colorectal Cancer

      • Others

    • Internal Beam Radiation Therapy

      • Prostate Cancer

      • Gynecological Cancer

      • Cervical Cancer

      • Breast Cancer

      • Penile Cancer

      • Others

  • Regional Outlook (Revenue, USD Million; 2018 - 2035)

    • North America

      • U.S.

      • Canada

      • Mexico

    • Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Denmark

      • Sweden

      • Norway

      • Rest of Europe

    • Asia Pacific

      • China

      • India

      • Japan

      • Australia

      • South Korea

      • Thailand

      • Rest of APAC

    • Latin America

      • Brazil

      • Argentina

      • Rest of LATAM

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

      • Rest of MEA

Related Reports

Table of Content

List Tables Figures

FAQ'S

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@marketinsightsresearch.com

Within 24 to 48 hrs.

You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email